Vives Marc, Monedero Pablo, Perez-Valdivieso José Ramón, Garcia-Fernandez Nuria, Lavilla Javier, Herreros Jesús, Bes-Rastrollo Maira
Department of Anesthesia and Critical Care, University of Navarra, Pamplona - Spain.
Int J Artif Organs. 2011 Apr;34(4):329-38. doi: 10.5301/IJAO.2011.7728.
Cardiac surgery-associated acute kidney injury requiring renal replacement therapy (RRT) is independently associated with mortality. Several risk scores have been developed to predict the need for RRT after cardiac surgery. We have compared and verified the external validity of the three main available scores for RRT prediction after cardiac surgery: the Thakar score, the Mehta tool, and the Simplified Renal Index.
The risk scores were calculated in a cohort of 1084 adult patients, 248 of whom required RRT, who underwent open-heart surgery in 24 Spanish hospitals in 2007. The performance of the systems was determined by examining their discrimination (areas under the receiver operating characteristic curves (aROC) and calibration (Lemeshow-Hosmer chi-square goodness-of-fit statistics).
The aROCs in the Thakar score, the Mehta tool, and the Simplified Renal Index were 0.82, 0.76 and 0.79, respectively. The three scoring systems were poorly calibrated and tended to underestimate the actual need for RRT.
The Thakar score and the Simplified Renal Index discriminated well between low - and high-risk patients in our cohort, and Thakar outperformed the Mehta tool. These best-performing scores may aid in the selection of optimal therapy, facilitate the planning of hospital resource utilization, improve preoperative counseling, select participants for clinical trials of renal-protective therapies and enable an accurate comparison between different institutions or surgeons.
心脏手术相关的急性肾损伤若需要肾脏替代治疗(RRT),则与死亡率独立相关。已经开发了几种风险评分来预测心脏手术后对RRT的需求。我们比较并验证了心脏手术后用于RRT预测的三种主要可用评分的外部有效性:塔卡尔评分、梅塔工具和简化肾指数。
对2007年在24家西班牙医院接受心脏直视手术的1084名成年患者进行队列研究,计算其风险评分,其中248名患者需要RRT。通过检查系统的辨别力(受试者操作特征曲线下面积(aROC))和校准(莱梅肖-霍斯默卡方拟合优度统计量)来确定系统的性能。
塔卡尔评分、梅塔工具和简化肾指数的aROC分别为0.82、0.76和0.79。这三种评分系统校准不佳,往往低估了对RRT的实际需求。
在我们的队列中,塔卡尔评分和简化肾指数在低风险和高风险患者之间有良好的辨别力,且塔卡尔评分优于梅塔工具。这些表现最佳的评分可能有助于选择最佳治疗方案,促进医院资源利用规划,改善术前咨询,选择肾保护治疗临床试验的参与者,并能够在不同机构或外科医生之间进行准确比较。